Mutations in SF3B1 gene are selected independently on ATM/TP53 status and reduce the time to first treatment in CLL patients.

HLOŽKOVÁ, Michaela, Jana FIGULOVÁ, Veronika NAVRKALOVÁ, Jitka MALČÍKOVÁ, Jana ŠMARDOVÁ, Nikola TOM, Yvona BRYCHTOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Martin TRBUŠEK. Mutations in SF3B1 gene are selected independently on ATM/TP53 status and reduce the time to first treatment in CLL patients. In Haematologica (2016); 101(s1): 417 (21st Congress of the EHA). 2016.

Basic information

Original name

Mutations in SF3B1 gene are selected independently on ATM/TP53 status and reduce the time to first treatment in CLL patients.

Authors

HLOŽKOVÁ, Michaela, Jana FIGULOVÁ, Veronika NAVRKALOVÁ, Jitka MALČÍKOVÁ, Jana ŠMARDOVÁ, Nikola TOM, Yvona BRYCHTOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Martin TRBUŠEK

Edition

Haematologica (2016); 101(s1): 417 (21st Congress of the EHA), 2016

---

Other information

Type of outcome

Konferenční abstrakt

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine

---

Links

MUNI/A/1028/2015, interní kód MU	Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit III (Acronym: VýDiTeHeMa III) Investor: Masaryk University, Category A
TE02000058, research and development project	Name: Centrum kompetence pro molekulární diagnostiku a personalizovanou medicínu (Acronym: MOLDIMED) Investor: Technology Agency of the Czech Republic